Pharmaxis says study points to larger market for lung drug
21 April, 2004 by Renate KrelleSydney-based Pharmaxis (ASX:PXS) believes the market for its Aridol lung function test has the potential to double, after a pilot Swiss study gave Aridol the stamp of approval for predicting patients' response to steroids used to treat chronic obstructive pulmonary disease.
Proteome Systems to assist in Huntington's research
20 April, 2004 by Graeme O'NeillA US foundation that sponsors research into Huntington's disease has turned to Sydney proteomics company Proteome Systems to search for prognostic markers and targets for drugs to treat the fatal neurodegenerative disorder.
Meditech says Phase II trial shows early promise
20 April, 2004 by Renate KrelleMeditech (ASX:MTR) will enrol an additional 12 patients in its Phase II trial, following promising early results from its HyCAMP treatment for advanced colorectal cancer patients at the Royal Melbourne Hospital.
Prima encouraged by Biomira result
16 April, 2004 by Melissa TrudingerPrima Biomed (ASX:PRR) has been cheered by clinical trial results from commercial partner Biomira.
By the pricking of my thumbs: shark and crustacean extracts may fight osteoarthritis
15 April, 2004 by Graeme O'NeillCan an extract of shark cartilage and crustacean shells alleviate the pain and inflammation of symptoms of osteoarthritis, the most common disease of aging?
pSivida raises $21 million as clinical trials approach
15 April, 2004 by Melissa TrudingerPerth-based nanotechnology company pSivida (ASX: PSD) has raised $21 million in an international placement - enough cash to see the company through to 2006, when it expects its first revenues.
Glaxo award winner getting more out of LIF
15 April, 2004 by Melissa TrudingerProf Doug Hilton, a researcher at the Walter and Eliza Hall Institute in Melbourne, has been awarded this year's GlaxoSmithKline award for research excellence, for his work on cell signalling.
J&J profit jumps, earnings forecast raised
14 April, 2004 by Staff WritersJohnson & Johnson's first-quarter earnings have jumped 20 per cent on higher sales of prescription drugs and medical devices, prompting it to raise its full-year profit forecast.
Biotech Capital kicks off expansion plans with $3.8m buyback
14 April, 2004 by Renate KrelleShareholders of Biotech Capital (ASX:BTC) have approved a $3.8 million buyback of shares and options held by the Challenger Group.
Gradiflow graduates to validation stage
14 April, 2004 by Melissa TrudingerLife Technologies (formerly Gradipore, ASX: GDP) has announced that it has moved into the second phase of its development agreement with US company Hematech.
Biotech startup Epichem opens for business
13 April, 2004 by Melissa TrudingerState of the art medicinal chemistry facilities were opened on the Murdoch University campus by the WA Minister for Development Clive Brown last week for biotech start up Epichem.
Ventracor ramps up manufacturing capacity for European trials
13 April, 2004 by Renate KrelleVentracor (ASX:VCR) today announced it has commissioned a new facility for manufacturing its VentrAssist artificial heart device. VCR will expand its current clean-room space, establishing a 260 square meter clean room and manufacturing facility in Sydney’s Chatswood.
Prana surges on study validating its metal-ion theory
13 April, 2004 by Graeme O'NeillShares in Melbourne drug-discovery company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) have surged by some 30 per cent after the Journal of Neuroscience published a new study last week that further validates the metal-ion theory of Alzheimer’s developed by Prana founder and Dr Ashley Bush.
Eiffel moves to Sydney
08 April, 2004 by Renate KrelleMelbourne’s loss was Sydney’s gain today, when drug re-engineering company Eiffel Technologies (ASX:EIF) announced it would be upping stakes and moving its head office to Sydney’s biotechnology neighbourhood of North Ryde, adjoining its new semi-commercial production facility.
Norwood to back animal conservation research
07 April, 2004 by Melissa TrudingerMelbourne biotech Norwood Abbey (ASX:NAL) is to sponsor a Monash Institute of Reproduction and Development group dedicated to research into the conservation and preservation of Australian animals.
